These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15322734)

  • 1. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.
    Kivistö KT; Zukunft J; Hofmann U; Niemi M; Rekersbrink S; Schneider S; Luippold G; Schwab M; Eichelbaum M; Fromm MF
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):124-30. PubMed ID: 15322734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra.
    Cao J; Chen X; Liang J; Yu XQ; Xu AL; Chan E; Wei D; Huang M; Wen JY; Yu XY; Li XT; Sheu FS; Zhou SF
    Drug Metab Dispos; 2007 Apr; 35(4):539-53. PubMed ID: 17220245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
    Shaik N; Giri N; Pan G; Elmquist WF
    Drug Metab Dispos; 2007 Nov; 35(11):2076-85. PubMed ID: 17709369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.
    Gong IY; Mansell SE; Kim RB
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):164-70. PubMed ID: 22958812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
    J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
    Geyer J; Gavrilova O; Petzinger E
    J Vet Pharmacol Ther; 2009 Feb; 32(1):87-96. PubMed ID: 19161460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments.
    Ejsing TB; Pedersen AD; Linnet K
    Hum Psychopharmacol; 2005 Oct; 20(7):493-500. PubMed ID: 16118767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.
    Luker GD; Rao VV; Crankshaw CL; Dahlheimer J; Piwnica-Worms D
    Biochemistry; 1997 Nov; 36(46):14218-27. PubMed ID: 9369495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of efflux transporters involved in distribution and disposition of apixaban.
    Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
    Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
    J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
    Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
    Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
    Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
    Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
    Swed A; Eyal S; Madar I; Zohar-Kontante H; Weiss L; Hoffman A
    Mol Pharm; 2009; 6(6):1883-90. PubMed ID: 19722701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.
    Takeuchi T; Yoshitomi S; Higuchi T; Ikemoto K; Niwa S; Ebihara T; Katoh M; Yokoi T; Asahi S
    Pharm Res; 2006 Jul; 23(7):1460-72. PubMed ID: 16779700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.
    Yamazaki M; Neway WE; Ohe T; Chen I; Rowe JF; Hochman JH; Chiba M; Lin JH
    J Pharmacol Exp Ther; 2001 Mar; 296(3):723-35. PubMed ID: 11181899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrier.
    Yamamoto C; Murakami H; Koyabu N; Takanaga H; Matsuo H; Uchiumi T; Kuwano M; Naito M; Tsuruo T; Ohtani H; Sawada Y
    J Pharm Pharmacol; 2002 Aug; 54(8):1055-63. PubMed ID: 12195819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
    de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.